1 **CATEGORY: INFECTIOUS DISEASE**

2

3 **TITLE: EVALUATION OF THE ROCHE ELECSYS ANTI-SARS-COV-2**
4 **ASSAY.**

5

6 **Authors:**

7 Lau CS¹, Hoo SP¹, Yew SF¹, Ong SK², Lum LT², Heng PY³, Tan JG³, Wong MS³,
8 Aw TC^{1,2,4,5*}

9 1. Department of Laboratory Medicine, Changi General Hospital, Singapore.

10 2. Department of Pathology, Sengkang General Hospital, Singapore.

11 3. Department of Laboratory Medicine, Khoo Teck Puat Hospital, Singapore.

12 4. Department of Medicine, National University of Singapore, Singapore.

13 5. Academic Pathology Program, Duke-NUS Medical School, Singapore.

14 * Corresponding Author

15 **Address:** Department of Laboratory Medicine, CHANGI GENERAL
16 HOSPITAL, 2 SIMEI STREET 3, SINGAPORE 529889

17 **E-mail:** tarchoon@gmail.com

18 **Phone:** +65 – 68504927

19 **Fax:** +65 – 64269507

20

21 **Disclosure:** All authors have nothing to disclose.

22 ABSTRACT

23

24 **Background:** Little is known about the performance of the Roche novel severe acute
25 respiratory syndrome coronavirus 2 antibody (anti-SARS-CoV-2) assay. We provide an
26 extensive evaluation of this fully automated assay on the Cobas e801/e602 immunoassay
27 analysers.

28 **Methods:** We assessed the linearity, precision, and throughput of the Roche anti-SARS-
29 CoV-2 assay. Sensitivity was calculated from 349 SARS-CoV-2 polymerase chain reaction
30 (PCR) positive samples; specificity was determined from 714 coronavirus disease 2019
31 (COVID-19)-naïve samples. We examined cross-reactivity against other antibody positive
32 samples (syphilis, RF, ANA, ds-DNA, influenza, dengue, HBV, HCV) and the anti-SARS-
33 CoV-2 kinetics.

34 **Results:** The assay cut-off index (COI) was linear up to 90.7. The inter-assay precision was
35 2.9% for a negative control (COI=0.1) and 5.1% for a positive control (COI=3.0). Assay time
36 is 18min and results are available 1 minute later; throughput for 300 samples was 76
37 minutes. No cross-reactivity was observed with other antibody positive samples; specificity
38 was 100%. The assay has a sensitivity of 97.1% 14 days after PCR positivity (POS) and
39 100% at ≥ 21 days POS; 48.2% of cases had anti-SARS-CoV-2 within 6 days POS. In 11
40 subjects in whom serum was available prior to a positive antibody signal (COI ≥ 1.0) the
41 interval between the last negative and first positive COI (time to “sero-conversion”) on
42 average is 3 days (range 1-6 days) and 4 more days (range 1-7) for the anti-SARS-CoV-2 to
43 plateau.

44 **Conclusion:** The Roche anti-SARS-CoV-2 assay shows excellent performance with minimal
45 cross-reactivity from other viral and confounding antibodies. Antibody development and
46 sero-conversion appears quite early.

47

48 **ABBREVIATIONS**

49 SARS-CoV-2 – Novel severe acute respiratory syndrome coronavirus 2

50 COVID-19 – Coronavirus disease 2019

51 Anti-SARS-CoV-2 – SARS-CoV-2 antibody

52 FDA – Food and Drug Administration

53 HCV – Hepatitis C

54 HBV – Hepatitis B

55 RF – Rheumatoid factor

56 HCWs – Health care workers

57 COI – Cut-off index

58 PCR – Polymerase chain reaction

59 CV – Inter-assay precision

60 PPA – Positive percentage agreement

61 NPA – Negative percentage agreement

62 POS – Post positive PCR

63 PPV – Positive predictive value

64 NPV – Negative predictive value

65 CDC – Centers for Disease Control and Prevention

66 PPE – Personal protective equipment

67 ANA – anti-nuclear antibody

68 Anti-ds-DNA – double-stranded DNA antibody

69 INTRODUCTION

70 The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a
 71 global pandemic. Coronavirus disease 2019 (COVID-19) can present with a range of
 72 symptoms (1, 2) and inflicts a disturbingly higher fatality rate in older patients (3). Viral testing
 73 (nucleic acid) remains the recommended diagnostic test for infection (4, 5). However, its long
 74 turn-around time has led to calls for more rapid tests like serology. Antibody testing can act
 75 as an indirect marker for infection, help identify patients with prior infection or exposure and
 76 can be performed relatively quickly. An immune response can develop (6) as soon as 10-13
 77 days after a COVID-19 infection (7, 8). However, the early rapid point-of-care tests (POCT)
 78 for anti-SARS-CoV-2 were fraught with inaccuracy. Roche Diagnostics has developed a
 79 SARS-CoV-2 antibody (anti-SARS-CoV-2) assay for use on its electrochemiluminescent-
 80 immunoassay analysers for the rapid, continuous testing of large numbers of samples. This
 81 assay has received approval from the Food and Drug Administration (FDA) (9) for laboratory
 82 use in May 2020. Some brief evaluations of this assay have been recently available as
 83 editorial letters (10, 11). We describe a more extensive evaluation of the Roche anti-SARS-
 84 CoV-2 assay on Cobas immunoassay analyzers across 3 institutions in Singapore.

85

86 MATERIALS AND METHODS

87 Patient cohorts

88 Residual serum samples from cases with suspected or confirmed SARS-CoV-2 infection
 89 from April to June 2020 were recruited from 3 institutions in Singapore: Changi General
 90 Hospital, Khoo Teck Puat Hospital and Sengkang General Hospital. For evaluating
 91 diagnostic sensitivity, 415 excess serum samples from COVID-19 cases (from 280 individual
 92 patients) testing positive for SARS-CoV-2 by PCR were used. For sensitivity analysis of an
 93 evolving biomarker like anti-SARS-CoV-2 at different time points in the disease evolution, it
 94 is customary to divide subjects by days from onset of symptoms or by days post initial PCR

positivity (POS). We elected to use POS rather than onset of symptoms as it is a more objective milestone and precludes confounding issues with patients who maybe asymptomatic or pre-symptomatic. Antibody positive samples [dengue N=74, hepatitis C (HCV) N=3, hepatitis B (HBV) N=12, syphilis N=1, antinuclear antibody (ANA) N=16, double-stranded DNA antibody (anti-ds-DNA) N=4, rheumatoid factor (RF) N=7] were recruited for cross-reactivity analysis; these samples were from ambulatory subjects with no suspicion for COVID-19 or acute respiratory illness. For diagnostic specificity, samples were obtained from 597 consenting healthcare workers (HCWs), 315 of whom had received their annual southern hemisphere influenza vaccination 4 weeks prior to testing. All samples were collected in plain serum tubes.

As the Roche anti-SARS-CoV-2 assay is a qualitative test, its sensitivity can be represented by the positive percentage agreement (PPA) between antibody positivity against all PCR positive patients tested. Conversely, the specificity of the test is represented by the negative percentage agreement (NPA) between antibody negativity against all control subjects.

To study sero-conversion, we examined SARS-CoV-2 PCR positive subjects with residual sera who were initially non-reactive for anti-SARS-CoV-2 but became reactive later.

Instrumentation and analysis

The Roche anti-SARS-CoV-2 assay is a sandwich immunoassay where biotinylated SARS-CoV-2 specific recombinant antigens and SARS-CoV-2 specific recombinant antigens labelled with ruthenium form a sandwich complex with anti-SARS-CoV-2. Streptavidin-coated microparticles are then added, and the complex becomes bound to a solid phase via interactions between biotin and streptavidin. Once the microparticles are captured onto the electrode surface and unbound substances are washed away, an electrical current at the electrode induces chemiluminescence. When compared to the mean chemiluminescent signal of a calibrator, an anti-SARS-CoV-2 index is derived with a reported cut-off index (COI) of 1.0 for positivity. Initially the assay did not include any quality control (QC) materials

and the manufacturer advised laboratories to prepare their own QC materials. A negative control derived from serum samples with a target COI of <0.8 and a positive control derived from serum samples with a target COI of 3-15 was recommended. Laboratories were also encouraged to watch their internal QCs carefully as the preliminary on-board stability of the reagents was 72 hours. The stated assay specificity in the package insert is 99.8% with a sensitivity of 100% for samples ≥ 14 days post symptom onset.

The molecular laboratories of all 3 hospitals employed real-time polymerase chain reaction (PCR) test systems that targeted at least 2 viral epitopes of SARS-CoV-2. Changi and Sengkang hospitals employed the Roche Cobas e801 while Khoo Teck Puat used the Cobas e602 immunoassay analyzer. Results from all three hospitals were pooled for sensitivity and specificity analyses while Changi General provided details of the technical analyses (precision, linearity and throughput). Inter-assay precision (CV) was analysed using 5 serum pools (including negative and positive controls prepared as per manufacturer recommendations, and 3 positive serum samples over a range of reactive COI values) run 5 times daily over 5 days, as per the CLSI EP15-A3 protocol (12). Assay linearity was assessed on several pools of reactive samples covering the clinically relevant range of COI. The laboratories at Changi General and Khoo Teck Puat are accredited by the College of American Pathologists.

Statistical analyses were performed using MedCalc software v19.3.1 (MedCalc, Ostend, Belgium). As this work was part of routine evaluation of new diagnostic assays, it was deemed exempt by our institutional review board.

RESULTS

Precision and linearity

The Roche assay showed good precision, with a CV of 2.9% for negative controls (mean COI = 0.1) and 5.1% for positive controls (mean COI = 3.0) (See Table 1); at higher COI

values (9.1, 18.9 and 42.4), the precision was very good (1.4%, 1.5%, 2.0%). The assay COI signal was found to be linear from 1.0 to 90.7 ($y = 181.44x - 1.3568$) and curvilinear rightwards thereafter (see Figure 1, Supplementary Table 1).

Table 1: Precision of the Roche anti-SARS-CoV-2 assay

< Table 1 >

Figure 1: Linearity plot of the Roche anti-SARS-CoV-2 assay.

< Figure 1 >

Throughput

At Changi General the anti-SARS-CoV-2 assay on the Roche Cobas e801 is run using two measuring cells. The Cobas e801 was able to analyse 50 samples in 29 minutes and 100 specimens in 39 minutes. When loaded with 300 samples (and not performing other routine tests simultaneously), the Cobas e801 completed the sample analysis in 76 minutes (see Supplementary Table 2).

Cross-reactivity

Out of the 315 HCWs who received their annual influenza vaccination 4 weeks prior to testing, none were reactive for anti-SARS-CoV-2. All cases positive for other antibodies (n=117) also tested negative for anti-SARS-CoV-2 (see Table 2).

Table 2: Cross-reactivity analysis for the Roche anti-SARS-CoV-2 assay.

< Table 2 >

Specificity

As there was no cross-reactivity with anti-SARS-CoV-2 in the 432 samples above (Table 2), we included them in diagnostic specificity analysis together with another 282 samples from other HCWs. None of these 714 samples were reactive on the Roche anti-SARS-CoV-2 assay, yielding a specificity of 100.00% (95% CI 99.47 to 100.00).

Sensitivity

Out of the samples recruited for diagnostic sensitivity testing (N=415), 66 were residual samples from inpatients (when they were not initially suspected of having COVID-19) but who subsequently tested positive for SARS-CoV-2 PCR. Therefore, these 66 samples were excluded from the sensitivity analysis. Of the remaining 349 samples (from 205 individual patients) the PPA increased to 97.1% after 14 days post positive PCR (POS), and to 100% after 21 days POS (see Table 3). Notably, 48.2% of patients had positive antibodies within the first week after their PCR diagnosis. Interestingly, of the 66 samples above (excluded from the sensitivity analyses) with late PCR diagnosis 48.5% were positive for anti-SARS-CoV-2.

Table 3: Roche assay sensitivity (positive percentage agreement) by days post positive PCR.

< Table 3 >

Positive and negative predictive values

Assuming a disease prevalence of 5%, the predictive value of the Roche anti-SARS-CoV-2 assay (specificity of 100% and sensitivity of >97% when used after 14 days POS) will be as follows: positive predictive value (PPV) 100.00% and negative predictive value (NPV) 99.9% (95%CI 99.41, 99.96); MedCalc did not provide the CI for the PPV.

197

198 Sero-conversion

199 Eleven subjects were available for sero-conversion study and the progression of their
200 antibody levels (COI) were plotted against days POS (See Figure 2 and Table 4). Using the
201 manufacturer recommended COI of 1.0 the interval for “sero-conversion” (last negative
202 reading to first positive reading), extrapolated from figure 2, ranged from 1-6 days with an
203 average of 3 days. In 8 of the 11 subjects the antibody levels plateaued over time (1-7 days
204 from positivity, mean of 4 days).

205

206 **Figure 2: SARS-CoV-2-Ab COI kinetics by days POS in patients with initial COI <1.0.**

207 **< Figure 2 >**

208

209 **Table 4: SARS-CoV-2-Ab COI trends by days POS in patients with initial COI <1.0.**

210 **< Table 4 >**

211

212 **DISCUSSION**

213 The Roche anti-SARS-CoV-2 assay shows good precision (CV of 2.9% and 5.1% at COI
214 levels of 0.1 and 3.0) and a linear signal response over a wide COI range (0.98 to 90.7). The
215 diagnostic sensitivity of the assay is 97.1% ≥ 14 days POS, or 100% after 21 days. The
216 diagnostic specificity is 100.0% in 714 non-COVID-19 samples tested. The PPV was
217 100.00%, and NPV 99.9% at ≥ 14 days POS. Our results are in close agreement with the
218 manufacturer's reported specifications. They are also in agreement with other evaluations of
219 the Roche anti-SARS-CoV-2 assay in the literature (10, 11, 13); the reported assay CV (2.1-
220 4.6%, 1.2-3.6%, <3.9%), test sensitivity at ≥ 14 days post-onset of symptoms (87.7%, 91.1%,

89.4%) and test specificity (100%, 100%, 98.7%) were similar to ours. This assay easily meets the US Centers for Disease Control and Prevention (CDC) and the FDA requirements for an acceptable SARS-CoV-2 serology test - >90% sensitivity and >95% specificity (14, 15). As the sensitivity/PPA only increases to over 90% after 14 days post PCR positivity, patients should not be tested earlier. This is also supported by other studies showing that it takes up to 11-14 days before anti-SARS-CoV-2 develop (16). Furthermore, the Roche assay has an excellent throughput, analysing 300 samples in 76 minutes. This is a major boon when processing large sample numbers from screening centres.

In our study we have used days POS to categorize our population. As COVID-19 can have asymptomatic and pre-symptomatic patients (17-19), using the presence of symptoms as a pre-selection criterion for inclusion will exclude asymptomatic and pre-symptomatic cases; days POS will mitigate against this. Notably, out of 66 leftover serum samples that were available before COVID-19 was suspected and PCR tested positive, 32 were already positive for anti-SARS-CoV-2. From the 11 patients with multiple longitudinal samples in figure 2, “sero-conversion” (interval between last negative point and first positive point) takes an average of 3 days, and that antibody titres plateau an average of 4 days later. A recent report (8) found that the time course of COVID19 antibodies (both IgG and IgM) tended to plateau in 6 days after they become positive in 19 subjects. Anti-SARS-CoV-2 has also been detected on the first day of PCR positivity (20) or within 7 days of symptom onset in 12.2% of patients (8). This indicates that in some patients, anti-SARS-CoV-2 development can occur earlier than expected.

A recent report (21) found that SARS-CoV-2 infection may cause false-positive dengue antibody results. It is noteworthy that in patients with positive dengue serology (n = 74) we did not encounter any false positive anti-SARS-CoV-2. Our study also confirms that the assay remains specific even in patients positive for HCV, HBV, syphilis, ANA, ds-DNA and RF. Moreover, in 315 samples with post-influenza vaccination, none were positive for anti-SARS-CoV-2, reinforcing the fact that the Roche assay has little cross-reactivity with

influenza antibodies. The sero-negativity of most of our HCWs also underscores the adequacy of our personal protective equipment (PPE) measures. The PPE measures taken by hospital staff across institutions in Singapore are similar (22), and include the use of surgical masks in low-risk areas (non-COVID-19 inpatient rooms, afebrile patient zones in the emergency department, non-infectious disease clinics) and N95 respirators/eye protection/gowns/gloves in high-risk areas (COVID-19 isolation rooms, febrile patient zones in the emergency department). However, their lack of antibodies also means that most of these HCWs remain at risk for future COVID-19 infections and they should continue to rigorously enforce safety precautions.

The strength of this evaluation is that it is a multi-center collaborative effort with sufficient sample numbers for sensitivity, specificity and cross-reactivity analyses. A limitation of our study is that we have relatively fewer samples for cases after 14 days POS. Further studies on larger populations would be desirable. In addition, we do not have the sero-prevalence of SARS-CoV-2 in our community. At the time of this study, we created our own negative and positive control materials from patient sera based on manufacturer recommendations. However, control materials have since been supplied by the manufacturer. The on-board reagent stability of 72 hours in the initial manufacturer information sheet has also been updated to 14 days.

CONCLUSION

Our results show that the Roche anti-SARS-CoV-2 assay has excellent performance and is highly comparable both with the manufacturer's information and other published studies. With an excellent throughput, the Cobas e801 should be extremely useful in the tracking the spread of SARS-CoV-2 in various populations and for sero-prevalence studies. We have also found that anti-SARS-CoV-2 can develop early.

REFERENCES

- (1) Gandhi RT, Lynch JB, Del Rio C. Mild or Moderate Covid-19. N Engl J Med 24 April, 2020. [Epub ahead of print] Doi: 10.1056/NEJMcp2009249.
- (2) Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. N Engl J Med 15 May, 2020. [Epub ahead of print] Doi: 10.1056/NEJMcp2009575.
- (3) Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet 30 March, 2020. [Epub ahead of print] Doi: [https://doi.org/10.1016/S1473-3099\(20\)30243-7](https://doi.org/10.1016/S1473-3099(20)30243-7).
- (4) Centers for Disease Control and Prevention. Evaluating and Testing Persons for Coronavirus Disease 2019 (COVID-19). 2020. <https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-criteria.html>. (Accessed 20 June, 2020.)
- (5) The Royal College of Pathologists of Australia. Position Statement, COVID19 IgG/IgM Rapid POCT Tests. 2020. <https://www.rcpa.edu.au/getattachment/bf9c7996-6467-44e6-81f2-e2e0cd71a4c7/COVID19-IgG-IgM-RAPID-POCT-TESTS.aspx>. (Accessed 20 June, 2020.)
- (6) U.S. Food and Drug Administration. Important Information on the Use of Serological (Antibody) Tests for COVID-19 - Letter to Health Care Providers. 2020. <https://www.fda.gov/medical-devices/letters-health-care-providers/important-information-use-serological-antibody-tests-covid-19-letter-health-care-providers>. (Accessed 20 June, 2020.)
- (7) Liu W, Liu L, Kou G, Zheng Y, Ding Y, Ni W, et al. Evaluation of Nucleocapsid and Spike Protein-based ELISAs for 2 detecting antibodies against SARS-CoV2. J Clin Microbiol 30 March, 2020. [Epub ahead of print] Doi: 10.1128/JCM.00461-20.
- (8) Long Q, Liu B, Deng H, Wu G, Deng K, Chen Y, et al. Antibody Responses to SARS-CoV-2 in Patients With COVID-19. Nat Med 29 April, 2020. [Epub ahead of print] Doi: 10.1038/s41591-020-0897-1.

- 301 (9) United States Food and Drug Administration. May 2, 2020, Tammy Dean, Elecsys Anti-
302 SARS-CoV-2, Roche Diagnostics. 2020. <https://www.fda.gov/media/137602/download>.
303 (Accessed 15 June, 2020.)
- 304 (10) Favresse J, Eucher C, Elsen M, Marie TH, Dogne JM, Douxfils J. Clinical
305 performance of the Elecsys electrochemiluminescent immunoassay for the detection of
306 SARS-CoV-2 total antibodies. Clin Chem 2 June, 2020. [Epub ahead of print] Doi:
307 <https://doi.org/10.1093/clinchem/hvaa131>.
- 308 (11) Tang MS, Hock KG, Logsdon NM, Hayes JE, Gronowski AM, Anderson NW, et al.
309 Clinical Performance of the Roche SARS-CoV-2 Serologic Assay. Clin Chem 2 June,
310 2020. [Epub ahead of print] Doi: <https://doi.org/10.1093/clinchem/hvaa132>.
- 311 (12) Clinical and Laboratory Standard Institute (CLSI). User Verification of Precision and
312 Estimation of Bias; Approved Guideline-Third Edition, CLSI document EP15-A3. PA
313 Wayne; CLSI 2014.
- 314 (13) Public Health England. Evaluation of the Roche Elecsys AntiSARS-CoV-2 serology
315 assay for the detection of anti-SARSCoV-2 antibodies. 2020.
316 [https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/887222/PHE_Evaluation_of_Roche_Elecsys_anti_SARS_CoV_2.pdf)
317 [_data/file/887222/PHE_Evaluation_of_Roche_Elecsys_anti_SARS_CoV_2.pdf](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/887222/PHE_Evaluation_of_Roche_Elecsys_anti_SARS_CoV_2.pdf).
318 (Accessed 15 June, 2020.)
- 319 (14) Centers for Disease Control and Prevention. Interim Guidelines for COVID-19
320 Antibody Testing. 2020. [https://www.cdc.gov/coronavirus/2019-](https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-guidelines.html)
321 [ncov/lab/resources/antibody-tests-guidelines.html](https://www.cdc.gov/coronavirus/2019-ncov/lab/resources/antibody-tests-guidelines.html). (Accessed 16 June, 2020.)
- 322 (15) US Food and Drug Administration. EUA Authorized Serology Test Performance.
323 2020. [https://www.fda.gov/medical-devices/emergency-situations-medical-devices/eua-](https://www.fda.gov/medical-devices/emergency-situations-medical-devices/eua-authorized-serology-test-performance)
324 [authorized-serology-test-performance](https://www.fda.gov/medical-devices/emergency-situations-medical-devices/eua-authorized-serology-test-performance). (Accessed 16 June, 2020.)
- 325 (16) Zhao J, Yuan Q, Wang H, Liu W, Liao X, Su Y, et al. Antibody Responses to SARS-
326 CoV-2 in Patients of Novel Coronavirus Disease 2019. Clin Infect Dis 28 March, 2020.
327 [Epub ahead of print] Doi: 10.1093/cid/ciaa344.

- (17) Mizumoto K, Kagaya K, Zarebski A, Chowell G. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. *Euro Surveill* 12 March, 2020. [Epub ahead of print] Doi: 10.2807/1560-7917.ES.2020.25.10.2000180.
- (18) Wei WE, Li Z, Chiew CJ, Yong SE, Toh MP, Lee VJ. Presymptomatic Transmission of SARS-CoV-2 — Singapore, January 23–March 16, 2020. *MMWR Morb Mortal Wkly Rep* 2020; 69: 411–415.
- (19) Li G, Li W, He X, Cao Y. Asymptomatic and Presymptomatic Infectors: Hidden Sources of COVID-19 Disease. *Clin Infect Dis* 9 April, 2020. [Epub ahead of print] Doi: 10.1093/cid/ciaa418.
- (20) Bryan A, Pepper G, Wener MH, Fink SL, Morishima C, Chaudhary A, et al. Performance Characteristics of the Abbott Architect SARS-CoV-2 IgG Assay and Seroprevalence in Boise, Idaho. *J Clin Microbiol* 7 May, 2020. [Epub ahead of print] Doi: 10.1128/JCM.00941-20.
- (21) Yan G, Lee CK, Lam L, Yan B, Chua YX, Lim A, et al. Covert COVID-19 and false-positive dengue serology in Singapore. *Lancet* 4 March, 2020. [Epub ahead of print] Doi: [https://doi.org/10.1016/S1473-3099\(20\)30158-4](https://doi.org/10.1016/S1473-3099(20)30158-4).
- (22) Then HL, Lim DW, Kyaw WM, Loh J, Lee LT, Ang B, et al. Responding to the COVID-19 Outbreak in Singapore: Staff Protection and Staff Temperature and Sickness Surveillance Systems. *Clin Infect Dis* 21 April, 2020. [Epub ahead of print] Doi: 10.1093/cid/ciaa468.

Table 1: Precision of the Roche anti-SARS-CoV-2 assay

Pool ID	Pool type	Min Index	Max Index	Mean COI	SD	%CV
1	Negative control (patient sera)	0.074	0.084	0.078	0.002	2.87
2	Positive control (patient sera)	2.770	3.280	2.991	0.153	5.11
3	S1	8.840	9.260	9.065	0.129	1.43
4	S2	18.200	19.400	18.856	0.277	1.47
5	S3	40.700	43.700	42.444	0.850	2.00

Table 2: Cross-reactivity analysis for the Roche anti-SARS-CoV-2 assay.

	N	Roche negative	Roche positive
Recent influenza vaccination	315	315	0
Dengue fever	74	74	0
Anti-HCV	3	3	0
Hepatitis B*	12	12	0
Syphilis antibodies	1	1	0
Anti-nuclear antibodies	16	16	0
Anti-dsDNA	4	4	0
RF positive	7	7	0
Total	432	432	0

* Hepatitis B cases included various combinations of HBsAg, anti-HBc IgM, HBeAg and anti-HBe.

Table 3: Roche assay sensitivity (positive percentage agreement) by days post positive PCR.

Days POS	N	Antibody positive	Antibody negative	PPA (%)	95% CI
0-6	189	91	98	48.2	40.84 to 55.52
7-13	90	68	22	75.6	65.36 to 84.00
14-20	34	32	2	94.1	80.32 to 99.28
≥14	70	68	2	97.1	90.06 to 99.65
≥21	36	36	0	100.0	90.26 to 100.00

398 **Table 4: SARS-CoV-2-Ab COI trends by days POS in patients with initial COI <1.0.**

Patient	Days POS	COI	POS day when COI $\geq 1.0^*$	Interval between negative to COI ≥ 1.0	POS day of plateau*	Interval to plateau*
A	0	0.08	4+	5	11+	7
	2	0.09				
	7	7.59				
	11	9.98				
B	0	0.08	2+	3	NA	NA
	1	0.09				
	4	6.03				
	6	21.0				
C	1	0.09	3+	4	5+	2
	5	5.44				
	9	6.59				
	10	5.03				
D	3	0.08	9+	2	12+	3
	7	0.09				
	8	0.12				
	10	2.49				
	12	13.8				
	14	5.86				
	17	7.19				
	19	12.2				
E	0	0.08	5+	2	11+	6
	1	0.09				
	5	0.51				
	7	2.36				
	11	12.6				
	15	13.1				
F	4	0.08	6+	1	10+	4
	6	0.15				
	7	1.17				
	10	14.7				
	14	15.9				
	16	14.3				
G	2	0.08	15+	6	NA	NA
	6	0.19				
	12	0.35				
	18	2.72				
H	0	0.07	5+	2	9+	4
	1	0.07				
	2	0.07				
	3	0.11				
	4	0.13				
	6	6.26				
	7	9.27				
	8	13.9				
	9	17.8				
	12	18.6				
	15	12.7				
	19	10.4				
I	0	0.11	2+	4	NA	NA
	1	0.19				
	5	7.98				
J	2	0.12	4+	2	8+	4
	4	0.34				
	6	10.3				
	8	27.6				
	10	26.9				
	13	38.5				

K	2	0.12	3+	2	4+	1
	4	1.99				
	9	2.11				
	12	1.76				
	14	1.59				
	18	1.96				
	22	4.24				

* based on interpolation from figure 2.

399